
RAPP Stock Forecast & Price Target
RAPP Analyst Ratings
Bulls say
Rapport Therapeutics is a clinical-stage biotechnology company focused on the development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's lead asset RAP-219, an AMPA modulator that selectively targets TARPγ8, is currently in development for focal onset epilepsy, generalized epilepsy, and bipolar mania. The company's portfolio also includes two discovery-stage nicotinic acetylcholine receptor programs for the treatment of chronic pain and hearing disorders. With a long half-life and potential to address the kindling effect of repeated episodes in both epilepsy and mania, RAP-219 presents a strong opportunity for addressing relapse and filling a gap in the current treatment landscape for patients with bipolar disorder. Additionally, the company has a solid financial outlook, with a projected peak sales of $3.3B for RAP-219.
Bears say
Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule medications for neurological and psychiatric conditions. However, with stiff competition in the epilepsy and manic bipolar markets and dependence on third-party suppliers for production, there are significant commercial and manufacturing risks for the company. While its lead asset RAP-219 has potential, there is no guarantee of market share success and potential delays in clinical trials.
This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RAPP Analyst Forecast & Price Prediction
Start investing in RAPP
Order type
Buy in
Order amount
Est. shares
0 shares